Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.78 |
| ▸ | VDR | P11473 | 11/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13343100 | 1.00 | CYP24A1 (0.78) | CYP24A1VDR | |
| SCHEMBL13824840 | 1.00 | CYP24A1 (0.78) | CYP24A1VDR | |
| SCHEMBL14802244 | 0.97 | CYP24A1 (0.77) | CYP24A1VDR | |
| SCHEMBL22422513 | 0.97 | CYP24A1 (0.77) | CYP24A1VDR | |
| SCHEMBL12641460 | 0.97 | CYP24A1 (0.77) | CYP24A1VDR | |
| SCHEMBL12190408 | 0.97 | CYP24A1 (0.77) | CYP24A1VDR | |
| SCHEMBL12371707 | 0.97 | CYP24A1 (0.77) | CYP24A1VDR | |
| SCHEMBL9010586 | 0.94 | VDR (0.79) | CYP24A1VDR | |
| SCHEMBL19601388 | 0.94 | VDR (0.79) | CYP24A1VDR | |
| SCHEMBL861063 | 0.94 | VDR (0.79) | CYP24A1VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440647-B2 | 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440647-B2 | 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130018021-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018021-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-7745404-B2 | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745404-B2 | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7713952-B2 | 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7566696-B2 | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566696-B2 | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080146491-A1 | USE OF CALCITONIN AND CALCITONIN-LIKE PEPTIDES TO TREAT AND PREVENT MULTIPLE SCLEROSIS | DELUCA HECTOR F | 2008-06-19 | — | — | US | disclosed |
| US-20080146491-A1 | USE OF CALCITONIN AND CALCITONIN-LIKE PEPTIDES TO TREAT AND PREVENT MULTIPLE SCLEROSIS | DELUCA HECTOR F | 2008-06-19 | — | — | US | disclosed |
| US-20070249567-A1 | 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-7244719-B2 | 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244719-B2 | 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7241749-B2 | 2α-Methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241749-B2 | 2α-Methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070105774-A1 | Administering an appropriate dosage schedule of a bone calcium resorption inhibitor like alendronate and a toxic dose of a vitamin D compounds like 1, alpha 25-dihydroxyvitamin D3 without developing hypercalcemia | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105774-A1 | Administering an appropriate dosage schedule of a bone calcium resorption inhibitor like alendronate and a toxic dose of a vitamin D compounds like 1, alpha 25-dihydroxyvitamin D3 without developing hypercalcemia | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105774-A1 | Administering an appropriate dosage schedule of a bone calcium resorption inhibitor like alendronate and a toxic dose of a vitamin D compounds like 1, alpha 25-dihydroxyvitamin D3 without developing hypercalcemia | CALCA, CALCRL, CYP24A1 | CYP24A1 3/4885VDR 7/4885 |
| US-20130018021-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | CYP24A1, CYP27B1, CD14 | CYP24A1 1/4885VDR 4/4885 |
| US-20070249567-A1 | 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses | CYP27B1, CYP24A1, VDR | CYP24A1 2/4885VDR 3/4885 |
| US-20080146491-A1 | USE OF CALCITONIN AND CALCITONIN-LIKE PEPTIDES TO TREAT AND PREVENT MULTIPLE SCLEROSIS | CALCA, CALCB, CALCRL | CYP24A1 7/4885VDR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.